Compare NSSC & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NSSC | EVO |
|---|---|---|
| Founded | 1969 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4553 |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 934.1M |
| IPO Year | 1994 | N/A |
| Metric | NSSC | EVO |
|---|---|---|
| Price | $45.83 | $3.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $48.17 | $7.00 |
| AVG Volume (30 Days) | ★ 340.8K | 74.4K |
| Earning Date | 05-04-2026 | 04-08-2026 |
| Dividend Yield | ★ 1.32% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.72 | N/A |
| Revenue | ★ $181,621,000.00 | N/A |
| Revenue This Year | $13.63 | $1.37 |
| Revenue Next Year | $10.05 | $10.05 |
| P/E Ratio | $63.08 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $21.35 | $2.31 |
| 52 Week High | $47.61 | $4.80 |
| Indicator | NSSC | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 66.59 | 63.79 |
| Support Level | $41.75 | $2.87 |
| Resistance Level | $47.46 | $3.78 |
| Average True Range (ATR) | 1.22 | 0.09 |
| MACD | 0.61 | 0.10 |
| Stochastic Oscillator | 94.40 | 78.38 |
NAPCO Security Technologies Inc manufactures security products, encompassing access control systems, door-locking products, intrusion and fire alarm systems and video surveillance products. Its products are used for various applications which includes alarm systems like automatic communicators, combination control panels/digital communicators and digital keypad systems, fire alarm control panel and area detectors mainly used for commercial, residential, institutional, industrial and governmental uses. Geographically, the company derives a majority of its revenue from the United States.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.